Sogroya
Procedural steps taken and scientific information after the authorisation
Application 
Scope
number
Opinion/ 
Commission 
Product 
Summary
Notification1 
Decision 
Information 
issued on
Issued2 / 
affected3 
amended 
on
X/0006/G
This was an application for a group of variations.
25/05/2023
24/07/2023
SmPC, 
Refer to the scientific discussion:
Annex I_2.(c) Change or addition of a new 
strength/potency
C.I.6.a - Change(s) to therapeutic indication(s) -
Addition of a new therapeutic indication or
modification of an approved one
Labelling and 
PL
EMEA/H/C/005030/X/0006/G
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
PSUSA/10920
Periodic Safety Update EU Single assessment - 
16/03/2023
n/a
PRAC Recommendation - maintenance
/202208
somapacitan
II/0004/G
This was an application for a group of variations.
24/11/2022
n/a
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS
B.I.c.1.c - Change in immediate packaging of the AS 
- Liquid ASs (non sterile)
B.I.a.4.d - Change to in-process tests or limits 
applied during the manufacture of the AS - Widening 
of the approved in-process test limits, which may 
have a significant effect on the overall quality of the 
AS
PSUSA/10920
Periodic Safety Update EU Single assessment - 
29/09/2022
n/a
PRAC Recommendation - maintenance
/202202
somapacitan
IB/0003/G
This was an application for a group of variations.
04/07/2022
n/a
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Page 2/3
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place
X/0001/G
This was an application for a group of variations.
24/02/2022
25/04/2022
SmPC, 
Labelling and 
PL
Annex I_2.(c) Change or addition of a new 
strength/potency
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes
PSUSA/10920
Periodic Safety Update EU Single assessment - 
07/04/2022
n/a
PRAC Recommendation - maintenance
/202108
somapacitan
Page 3/3
